Outcomes Stratified by Adapted Inclusion Criteria After Transcatheter Tricuspid Edge‐to‐Edge Repair

View at publisher
Authors: Giulio Russo, Daniela Pedicino, Marianna Adamo, Hannes Alessandrini, Martin Andreas, Daniel Braun, Kim Alexander Connelly, Gaetano Chiricolo, Paolo Denti, Rodrigo Estévez‐Loureiro, Neil Fam, Rebecca T Hahn
+37 more Claudia Harr, Jörg Hausleiter, Dominique Himbert, Daniel Kalbacher, Edwin C. Ho, Azeem Latib, Edith Lubos, Sebastian Ludwig, Gianluca Massaro, Philipp Lurz, Marco Metra, Vanessa Moñivas, Georg Nickenig, Giovanni Pedrazzini, Alberto Pozzoli, Fabien Praz, Joseph Rodes-Cabau, Christian Besler, Karl‐Philipp Rommel, Joachim Schöfer, Andrea Scotti, Kerstin Piayda, Giuseppe Massimo Sangiorgi, Horst Sievert, Gilbert H.L. Tang, Isaac Pascual, Hölger Thiele, Florian Schlotter, Andrea Natale, Ralph Stephan von Bardeleben, John G. Webb, Stephan Windecker, Martin Leon, Maurice L. Enriquez-Sarano, Francesco Maisano, Stefan Bloechlinger, Maurizio Taramasso
Cited by: 1
References: 19

Abstract

BACKGROUND: Recent trials demonstrated that tricuspid transcatheter edge-to-edge repair (T-TEER) is particularly effective for symptoms and quality of life improvement. However, its effect on prognosis is still unclear. Moreover, the applicability of trials inclusion/exclusion criteria has not been investigated. AIMS: The aim of the present study is to investigate the applicability of TRILUMINATE and Tri.Fr trials inclusion and exclusion criteria on real-world patients from TRIVALVE registry, and to evaluate their effects on outcomes. METHODS: Patients undergoing T-TEER were selected from the TRIVALVE registry and, according to inclusion and exclusion criteria, divided in four groups: TRILUMINATE eligible versus ineligible and Tri.Fr eligible versus ineligible patients. TRILUMINATE and Tri.Fr analysis were conducted separately. RESULTS: From a total of 664 patients of the TRIVALVE registry, 520 and 519 were included in the TRILUMINATE and Tri.Fr analysis, respectively. In particular, 240 patients (46%) met the TRILUMINATE criteria and 260 (50%) those of Tri.Fr. Baseline characteristics were significantly different between trials' eligible and ineligible patients. TRILUMINATE-eligible patients showed significant lower mortality/rehospitalization compared to ineligible ones (12% vs. 25%, p = 0.028), as well as Tri.Fr-eligible versus ineligible ones (15% vs. 22%, p = 0.007). CONCLUSIONS: In patients with TR undergoing T-TEER, inclusion and exclusion criteria of TRILUMINATE and Tri.Fr are applicable to around half of real-world patients. Patients matching trials criteria have lower mortality/rehospitalization.

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Aortic Disease and Treatment Approaches Spine and Intervertebral Disc Pathology

Publication details

Journal / source
Catheterization and Cardiovascular Interventions
Publisher
Wiley
Publication date
21 July 2026
Language
EN